The Immunology of Obstructive Lung Disease and Emergence of Biologic Treatment
Released On
June 30, 2025
Expires On
June 29, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Pulmonology
Topic(s)
Asthma, COPD, Respiratory
Providers/Grant Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc., Sanofi, and Genentech, a member of the Roche Group.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 contact hour of nursing continuing professional development credit
- PAs — maximum of 1.0 AAPA Category 1 CME credit
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for pulmonary specialists and other members of the health care team who care for patients with obstructive lung diseases such as COPD and asthma.
Program Overview
Asthma and COPD remain two of the most common and complex obstructive lung diseases, affecting a significant portion of the population. While these conditions share clinical symptoms, their distinct immunologic underpinnings call for nuanced, personalized treatment strategies. Enhance your understanding of lung immunobiology and improve your utilization of biologics in clinical practice.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the underlying immunology associated with certain obstructive lung diseases
- Assess the barriers that have limited the use of biologic therapies to treat obstructive lung diseases and identify strategies to potentially overcome them
- Evaluate recent trial results for the use of biologics to treat obstructive lung diseases and consider the implications for clinical practice
Faculty
Stephanie Christenson, MD
Associate Professor, Medicine
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
UCSF Health
San Francisco, CA
Nick Hanania, MD, MS
Director, Airways Clinical Research Center
Professor of Medicine
Chief, Section of Pulmonary, Critical Care and Sleep Medicine
Ben Taub Hospital
Baylor College of Medicine
Houston, TX
Frank Sciurba, MD
Professor of Medicine and Education
Director of Emphysema/COPD Research Center and Clinical Pulmonary Physiology Laboratories
University of Pittsburgh
Pittsburgh, PA
Accredited Provider
Provided by the American Thoracic Society
Accreditation Statement – American Thoracic Society The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation (American Thoracic Society)
The American Thoracic Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hour.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 29, 2026. PAs should only claim credit with the extent of their participation.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pretest, completing the activity, and completing the posttest and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Credit Fulfillment
- If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download
Course Viewing Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers.
Additionally, this site and its activities are best viewed using the latest operating system for your device.
Disclosure of Unlabeled Use
The American Thoracic Society (ATS) and The France Foundation (TFF) require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ATS and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
ATS and TFF present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ATS and TFF and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or [email protected].